Anti-hMARCO treatment could thus be used as a combinatory immunotherapy with anti-CTLA-4/anti-PD-1/PD-L1 to improve the efficacy of checkpoint therapies in pancreatic cancer patients. The gene discussed is CTLA4; the disease is pancreatic neoplasm.